Suppr超能文献

干粉吸入器用于药物递送的性能的临床相关性。

The clinical relevance of dry powder inhaler performance for drug delivery.

作者信息

Demoly Pascal, Hagedoorn Paul, de Boer Anne H, Frijlink Henderik W

机构信息

Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve and University Hospital of Montpellier, 371 Ave. du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.

Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands.

出版信息

Respir Med. 2014 Aug;108(8):1195-203. doi: 10.1016/j.rmed.2014.05.009. Epub 2014 May 24.

Abstract

BACKGROUND

Although understanding of the scientific basis of aerosol therapy with dry powder inhalers (DPIs) has increased, some misconceptions still persist. These include the beliefs that high resistance inhalers are unsuitable for some patients, that extra fine (<1.0 μm) particles improve peripheral lung deposition and that inhalers with flow rate-independent fine particle fractions (FPFs) produce a more consistent delivered dose to the lungs.

OBJECTIVES

This article aims to clarify the complex inter-relationships between inhaler design and resistance, inspiratory flow rate (IFR), FPF, lung deposition and clinical outcomes, as a better understanding may result in a better choice of DPI for individual patients.

METHODS

The various factors that determine the delivery of drug particles into the lungs are reviewed. These include aerodynamic particle size distribution, the inspiratory manoeuvre, airway geometry and the three basic principles that determine the site and extent of deposition: inertial impaction, sedimentation and diffusion. DPIs are classed as either dependent or independent of inspiratory flow rate and vary in their internal resistance to inspiration. The effects of these characteristics on drug deposition in the airways are described using data from studies directly comparing currently available inhaler devices.

RESULTS

Clinical experience shows that most patients can use a high resistance DPI effectively, even during exacerbations. Particles in the aerodynamic size range from 1.5-5 μm are shown to be optimal, as particles <1.0 μm are very likely to be exhaled again while those >5 μm may impact on the oropharynx. For DPIs with a constant FPF at all flow rates, less of the delivered dose reaches the central and peripheral lung when the flow rate increases, risking under-dosing of the required medication. In contrast, flow rate-dependent inhalers increase their FPF output at higher flow rates, which compensates for the greater impaction on the upper airways as flow rate increases.

CONCLUSIONS

The technical characteristics of different inhalers and the delivery and deposition of the fine particle dose to the lungs may be important additional considerations to help the physician to select the most appropriate device for the individual patient to optimise their treatment.

摘要

背景

尽管对干粉吸入器(DPI)雾化治疗的科学基础的理解有所增加,但一些误解仍然存在。这些误解包括认为高阻力吸入器不适用于某些患者、超细微颗粒(<1.0μm)可改善外周肺沉积以及具有与流速无关的细颗粒分数(FPF)的吸入器可向肺部输送更一致剂量的药物。

目的

本文旨在阐明吸入器设计与阻力、吸气流量(IFR)、FPF、肺沉积和临床结果之间复杂的相互关系,因为更好地理解这些关系可能会为个体患者带来更好的DPI选择。

方法

回顾了决定药物颗粒输送到肺部的各种因素。这些因素包括空气动力学粒径分布、吸气动作、气道几何形状以及决定沉积部位和程度的三个基本原则:惯性碰撞、沉降和扩散。DPI分为依赖或不依赖吸气流量的类型,并且它们对吸气的内部阻力各不相同。使用直接比较现有吸入器装置的研究数据描述了这些特征对气道中药物沉积的影响。

结果

临床经验表明,大多数患者即使在病情加重期间也能有效使用高阻力DPI。空气动力学粒径范围为1.5 - 5μm的颗粒显示为最佳,因为<1.0μm的颗粒很可能再次呼出,而>5μm的颗粒可能会撞击口咽部。对于在所有流速下具有恒定FPF的DPI,当流速增加时,到达中央和外周肺的输送剂量会减少,存在所需药物剂量不足的风险。相比之下,依赖流速的吸入器在较高流速下会增加其FPF输出,这补偿了随着流速增加对上呼吸道的更大碰撞。

结论

不同吸入器的技术特征以及细颗粒剂量向肺部的输送和沉积可能是重要的额外考虑因素,有助于医生为个体患者选择最合适的装置以优化治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验